PepGen Surges on Positive Phase 2 DM1 Trial Update

PepGen Inc. (PEPG) is up 128.0% today. Here is some analysis on what might have caused this price movement.

Analysis: The sharp move appears tied mainly to PepGen’s positive Phase 2 FREEDOM2-DM1 update for PGN-EDODM1, which showed strong splicing correction and improvements across several functional measures in patients with myotonic dystrophy type 1. Investors also seem to be reacting to the therapy’s tolerability profile and to management’s statement that cash should fund operations into 2028, which reduces near-term financing pressure.

Details:

PepGen announced positive topline results from the 10 mg/kg cohort of its ongoing Phase 2 FREEDOM2-DM1 study, with mean splicing correction of 46.5% after four monthly doses.

The company highlighted improvements in video Hand Opening Time, hand grip strength, Timed Up and Go, and the 10-Meter Walk/Run Test, suggesting potential benefit across multiple disease symptoms.

PepGen said the treatment was generally well tolerated in this cohort, with no serious or severe adverse events, no dose-limiting toxicities, and no treatment discontinuations.

The company also said the 12.5 mg/kg cohort is fully enrolled, expects more data in the first half of 2027, and ended the quarter with $104.8 million in cash, cash equivalents, and marketable securities.

Sources:

PepGen, SEC, Yahoo Finance

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$PEPG Insider Trading Activity

$PEPG insiders have traded $PEPG stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $PEPG stock by insiders over the last 6 months:

KASRA KASRAIAN (Chief Technical Officer) sold 1,233 shares for an estimated $1,739

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$PEPG Hedge Fund Activity

We have seen 32 institutional investors add shares of $PEPG stock to their portfolio, and 43 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

RENAISSANCE TECHNOLOGIES LLC added 1,463,446 shares (+2576.5%) to their portfolio in Q2 2026, for an estimated $2,634,202
WOODLINE PARTNERS LP removed 1,311,021 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $2,359,837
PICTET ASSET MANAGEMENT HOLDING SA removed 1,306,783 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $2,352,209
AWM INVESTMENT COMPANY, INC. removed 1,230,925 shares (-67.2%) from their portfolio in Q2 2026, for an estimated $2,215,665
ADAR1 CAPITAL MANAGEMENT, LLC added 983,447 shares (+61.2%) to their portfolio in Q2 2026, for an estimated $1,770,204
MORGAN STANLEY removed 950,145 shares (-95.1%) from their portfolio in Q2 2026, for an estimated $1,710,261
GSA CAPITAL PARTNERS LLP added 809,412 shares (+1863.3%) to their portfolio in Q2 2026, for an estimated $1,456,941

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.